SEC Tracker
Get the app

MEI Pharma LITS

MEI Pharma FY 2021: revenue $34.8M; diluted EPS −$0.60

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers MEI Pharma reported for the year ended Jun 30, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$34.8MNo year-earlier figure tagged10-K/A income statement, on EDGAR
  2. Net income−$41.3MNo year-earlier figure tagged10-K/A income statement, on EDGAR
  3. Diluted EPS−$0.60No year-earlier figure tagged10-K/A income statement, on EDGAR
  4. Cash and cash equivalents$8.5MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K/A balance sheet, on EDGAR
  5. Cash from operations−$32.0MNo year-earlier figure tagged10-K/A cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when MEI Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Actinium Pharmaceuticals ATNM public float $44M, Jun 30, 2025
  2. Fortress Biotech FBIO public float $44M, Jun 30, 2025
  3. Actuate Therapeutics ACTU public float $42M, Jun 30, 2025
  4. Acumen Pharmaceuticals ABOS public float $45M, Jun 30, 2025
  5. Opus Genetics IRD public float $46M, Jun 30, 2025